QuantideX® qPCR BCR-ABL minor Kit (RUO)

BCR-ABL blood cancer cellsThe QuantideX® qPCR BCR-ABL minor Kit (RUO) is a clinical research tool enabling ultra-sensitive and precise detection of BCR-ABL1 minor fusion transcripts (e1a2) from whole blood specimens. Building on the simple workflow and best-in-class sensitivity established with the FDA-cleared QuantideX® qPCR BCR-ABL IS Kit, the minor Kit allows labs and clinical researchers to examine the biology of disease for this very rare but distinct leukemic variant with unprecedented ease.
Order the QuantideX qPCR BCR-ABL minor Kit

Features & Benefits

The QuantideX qPCR BCR-ABL minor Kit (RUO) delivers high performance through unmatched sensitivity and optimized laboratory efficiency.

Reduced Complexity
Ease-of-data analysis and reporting:

  • Leverages the QuantideX® qPCR BCR-ABL IS Kit workflow concept for streamlined implementation
  • QuantideX qPCR Reporter provides automated calculation of BCR-ABL1/ABL1 % ratio and eliminates the need for manual calculation

Optimized Workflow
Valuable operator hands-on time has been significantly reduced through:

  • Multiplexed design amplifies and detects both fusion and control gene in the same reaction
  • All-inclusive reagents sourced and quality controlled together from a single vendor
  • Pre-mixed reagents allow fewer pipetting steps in mastermix preparation

Quality Performance
Detecting BCR-ABL1 minor transcripts robustly and reliably with a highly sensitive assay:

  • Ultra-sensitive Limit of Detection (LOD): Log reduction of 4.61 (0.0025% ratio)
  • Increased analytical sensitivity without compromising analytical specificity: incorporates Limit of Blank (LOB) to prevent miscalling of non-leukemic low positives
  • Armored RNA®-based standards provide true RNA quantification

Analytical Characteristics

  • Reproducible: Proven sensitivity based on rigorous testing criterion (Table 1)
  • Precise: Minimal variability across entire dynamic range of BCR-ABL1/ABL1 % ratios (Table 2)
  • Streamlined: Multiplexed design yields workflow and cost efficiencies (Figure 1)

Proven Sensitivity Based on Rigorous Testing Criterion
Table 1: LOD as determined by CLSI EP17-A2 guidelines by testing human RNA and cell line dilutions spanning lots, batch runs, days, operators and instruments.

Minimal Variability across Entire Dynamic Range

Table 2: Assay precision determined by testing 4 different log reduction (LR) levels in human RNA, using 2 operators and 8 runs for a total of 192 data points.

 

Multiplexed Design Yields Workflow and Cost Efficiency
  

 

 

 


Figure 1: 
Comparison of a plate layout for 8 sample run on Asuragen plate (left) and an alternate non-multiplex assay (right): 19 reactions for Asuragen setup vs. 52 reactions on a non-multiplex assay setup

Ordering

Product Name Number of Reactions Catalog Number
QuantideX® qPCR BCR-ABL minor Kit (RUO) 60 49637

T 512.681.5200 or 877.777.1874
F 512.681.5202

QuantideX® qPCR BCR-ABL minor Kit

The BCR-ABL1 minor breakpoint (e1a2) constitutes a rare but distinct leukemic variant and accurate detection and quantitation of these fusion transcripts are paramount to improving outcomes for all chronic myeloid leukemia (CML) patients. The QuantideX® qPCR BCR-ABL minor Kit, an in vitro diagnostic (IVD) assay, enables ultra-sensitive detection of BCR-ABL1 minor fusion transcripts from whole blood specimens.

Order the QuantideX qPCR BCR-ABL minor Kit

Features & Benefits

The QuantideX qPCR BCR-ABL minor Kit marries improved efficiency with unprecedented sensitivity, empowering labs to assess the deepest molecular responses in patients harboring the minor breakpoint with the ease-of-use they’ve come to expect from Asuragen.

Reduced Complexity
Ease-of-data analysis and reporting:

  • Shares a common workflow with the QuantideX® qPCR BCR-ABL IS Kit to reduce training burden and streamline test implementation
  • Included software provides automated calculation of BCR-ABL1/ABL1 % ratio and the ability to report BCR-ABL Major on both the International Scale (IS) and copy number*

Optimized Workflow
Valuable operator hands-on time has been significantly reduced through:

  • Multiplexed design amplifies and detects both fusion and control gene in the same reaction
  • All necessary RT and qPCR reagents sourced and quality controlled together from a single vendor
  • Pre-mixed reagents allow fewer pipetting steps in mastermix preparation

Quality Performance
Detecting BCR-ABL1 minor transcripts robustly and reliably with a highly sensitive assay:

  • Ultra-sensitive Limit of Detection (LOD): Log reduction of 4.61 (0.0025% ratio)
  • Increased analytical sensitivity without compromising analytical specificity: incorporates Limit of Blank (LOB) to prevent miscalling of non-leukemic low positives
  • Armored RNA®-based standards provide true RNA quantification

 

 

 

Analytical Characteristics

  • Reproducible: Proven sensitivity based on rigorous testing criterion (Table 1)
  • Precise: Minimal variability across entire dynamic range of BCR-ABL1/ABL1 % ratios (Table 2)
  • Streamlined: Multiplexed design yields workflow and cost efficiencies (Figure 1)

Proven Sensitivity Based on Rigorous Testing Criterion
Table 1: LOD as determined by CLSI EP17-A2 guidelines by testing human RNA and cell line dilutions spanning lots, batch runs, days, operators and instruments.

Minimal Variability across Entire Dynamic Range

Table 2: Assay precision determined by testing 4 different log reduction (LR) levels in human RNA, using 2 operators and 8 runs for a total of 192 data points.

 

Multiplexed Design Yields Workflow and Cost Efficiency
  

 

 

 


Figure 1: 
Comparison of a plate layout for 8 sample run on Asuragen plate (left) and an alternate non-multiplex assay (right): 19 reactions for Asuragen setup vs. 52 reactions on a non-multiplex assay setup

Ordering

Product Name Number of Reactions Catalog Number
QuantideX® qPCR BCR-ABL minor Kit 60 49640

T +1 512.681.5200 or +1 877.777.1874
F +1 512.681.5202

Back To
Top